Our work highlights that SF3B1 mutations, recognized in the 2022 ELN risk classification (46) as an adverse prognostic marker if they are associated with intermediate or adverse risk AML, provide a genetic predisposition to copper overload–based therapies, offering a unique therapeutic angle for these patients. Here, SF3B1 is linked to acute myeloid leukemia.